Opus Genetics, Inc.是一家临床阶段的眼科生物制药公司,致力于开发和商业化用于治疗多种眼疾的疗法。Ocuphire的产品线目前包括针对眼部适应症的两种小分子候选产品。该公司的主要产品候选产品Nyxol眼药水是一种每日一次无防腐剂的甲磺酸酚妥拉明的眼药水配方,一种非选择性的α-1和α-2肾上腺素能拮抗剂,旨在减少瞳孔大小,目前正在开发有几种适应症,包括昏暗的灯光或夜视障碍,药理性散瞳和老花眼。Ocuphire的第二个候选产品APX3330是每天两次的口服片剂,旨在抑制与视网膜和脉络膜血管疾病(例如糖尿病性视网膜病变和糖尿病性黄斑水肿)相关的血管生成和炎症途径。
董事
名称
职位
Cam Gallagher
Independent Chairman of the Board and Director
George Magrath
Chief Executive Officer, Director
James S. Manuso
Independent Director
Sean Ainsworth
Independent Director
Susan K. Benton
Independent Director
Adrienne Graves
Director
Benjamin R. Yerxa
Director
Jean Bennett
Director
Richard J. Rodgers
董事
股东
名称
职位
George Magrath
Chief Executive Officer, Director
Joseph Schachle
Chief Operating Officer
Amy Rabourn
Senior Vice President of Finance
Bernhard Hoffmann
Senior Vice President of Corporate Development
Robert Gagnon
Chief Financial Officer and Principal Accounting Officer